404 related articles for article (PubMed ID: 19563467)
1. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.
Weiss G; Theurl I; Eder S; Koppelstaetter C; Kurz K; Sonnweber T; Kobold U; Mayer G
Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467
[TBL] [Abstract][Full Text] [Related]
2. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
[TBL] [Abstract][Full Text] [Related]
3. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
[TBL] [Abstract][Full Text] [Related]
4. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients.
Kato A; Tsuji T; Luo J; Sakao Y; Yasuda H; Hishida A
Am J Nephrol; 2008; 28(1):115-21. PubMed ID: 17943020
[TBL] [Abstract][Full Text] [Related]
5. Increased hepcidin-25 and erythropoietin responsiveness in patients with cardio-renal anemia syndrome.
Kato A
Future Cardiol; 2010 Nov; 6(6):769-71. PubMed ID: 21142632
[TBL] [Abstract][Full Text] [Related]
6. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients.
Costa E; Swinkels DW; Laarakkers CM; Rocha-Pereira P; Rocha S; Reis F; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Acta Haematol; 2009; 122(4):226-9. PubMed ID: 19887781
[No Abstract] [Full Text] [Related]
7. Serum prohepcidin and hepcidin in hemodialyzed patients undergoing iron therapy.
Malyszko J; Malyszko JS; Mysliwiec M
Kidney Blood Press Res; 2009; 32(4):235-8. PubMed ID: 19713706
[TBL] [Abstract][Full Text] [Related]
8. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients?
Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Mysliwiec M
Am J Nephrol; 2005; 25(6):586-90. PubMed ID: 16254410
[TBL] [Abstract][Full Text] [Related]
9. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients.
Arabul M; Gullulu M; Yilmaz Y; Eren MA; Baran B; Gul CB; Kocamaz G; Dilek K
Med Sci Monit; 2009 Nov; 15(11):CR583-7. PubMed ID: 19865058
[TBL] [Abstract][Full Text] [Related]
10. [The effect of tobacco smoking during pregnancy on concentration of pro-hepcidin and some parameters of iron metabolism in matched-maternal cord pairs].
Chełchowska M; Lewandowski L; Ambroszkiewicz J; Swiatek E; Gajewska J; Ołtarzewski M; Laskowska-Klita T
Przegl Lek; 2008; 65(10):474-8. PubMed ID: 19189526
[TBL] [Abstract][Full Text] [Related]
11. Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients.
Sonnweber T; Theurl I; Seifert M; Schroll A; Eder S; Mayer G; Weiss G
Nephrol Dial Transplant; 2011 Mar; 26(3):977-87. PubMed ID: 20826742
[TBL] [Abstract][Full Text] [Related]
12. Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin.
Malyszko J; Malyszko JS; Kozminski P; Mysliwiec M
Ren Fail; 2009; 31(10):876-83. PubMed ID: 20030521
[TBL] [Abstract][Full Text] [Related]
13. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation.
Kuragano T; Shimonaka Y; Kida A; Furuta M; Nanami M; Otaki Y; Hasuike Y; Nonoguchi H; Nakanishi T
Am J Nephrol; 2010; 31(6):534-40. PubMed ID: 20484891
[TBL] [Abstract][Full Text] [Related]
14. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate.
Peters HP; Laarakkers CM; Swinkels DW; Wetzels JF
Nephrol Dial Transplant; 2010 Mar; 25(3):848-53. PubMed ID: 19854845
[TBL] [Abstract][Full Text] [Related]
15. Serum pro-hepcidin as an indicator of iron status in dialysis patients.
Tsuchihashi D; Abe T; Komaba H; Fujii H; Hamada Y; Nii-Kono T; Tanaka M; Fukagawa M
Ther Apher Dial; 2008 Jun; 12(3):226-31. PubMed ID: 18503700
[TBL] [Abstract][Full Text] [Related]
16. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients.
Daschner M; Mehls O; Schaefer F
Clin Nephrol; 1999 Oct; 52(4):246-52. PubMed ID: 10543327
[TBL] [Abstract][Full Text] [Related]
17. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Am J Hematol; 2006 Nov; 81(11):832-7. PubMed ID: 16929540
[TBL] [Abstract][Full Text] [Related]
18. Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia.
Theurl I; Finkenstedt A; Schroll A; Nairz M; Sonnweber T; Bellmann-Weiler R; Theurl M; Seifert M; Wroblewski VJ; Murphy AT; Witcher D; Zoller H; Weiss G
Br J Haematol; 2010 Feb; 148(3):449-55. PubMed ID: 19863534
[TBL] [Abstract][Full Text] [Related]
19. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
20. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency.
Finkenstedt A; Bianchi P; Theurl I; Vogel W; Witcher DR; Wroblewski VJ; Murphy AT; Zanella A; Zoller H
Br J Haematol; 2009 Mar; 144(5):789-93. PubMed ID: 19120353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
